In terms of sex, the HR was 0.89 (95% CI: 0.840.94) for males and 0.82 (95% CI: 0.770.87) for females
For many people, this is the correct therapeutic dose that produces optimal results with manageable side effects
The disease affects approximately 1 million adults in the United States, according to the National MS Society, with varying clinical presentations including relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS)
References Abiona O, Wyatt D, Koner J, Mohammed A (2022) The optimisation of carrier selection in dry powder inhaler formulation and the role of surface energetics
Zeron, Y
It has received FDA Breakthrough Therapy designation for MASH (metabolic dysfunction-associated steatohepatitis), the liver condition formerly known as NASH